An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2018
Price : $35 *
At a glance
- Drugs Mivavotinib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 26 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as per business decision: no safety or efficacy concerns
- 21 Feb 2018 Planned initiation date changed from 5 Feb 2018 to 28 Feb 2018.
- 19 Jan 2018 Planned initiation date changed from 20 Dec 2017 to 5 Feb 2018.